Technology Management Maturity Assessment Model: An Exploratory Multi-Criteria Approach for Healthcare Organizations

Maturity Models are organizational management tools that have been developed and used for decades as organizations\u27 way of responding to the constant pressure of trying to achieve and maintain competitive advantage through concurrent innovation, quality improvement, and cost reduction. The decision makers in the healthcare industry have been no exception in reaping the benefits of determining the merits and weaknesses of strategies through systematic quality improvement provided by maturity models. Although there are many healthcare maturity models in literature, there is a lack of models that provides managers and decision makers with a systematic, multi-criteria, and quantifiable maturity model. This paper proposes an exploratory model to assess technology management maturity in healthcare organizations by using Hierarchical Decision Model (HDM). The model may help health organizations with pinpointing their strengths and weaknesses in the adoption and implementation of new technologies and technological approaches such as Learning Health Systems (LHS) and their socio-technical infrastructure, while giving them organizational and competitive self-awareness and guide them in setting their strategies and resource allocation. The model will serve as a much-needed technology management tool for hospitals to assess their technology management maturity for both public and organization\u27s advantage in a more effective way

Impact of Genomics on Biopharmaceutical Industry: Rare Diseases as Disruptive Innovation

The multinational biopharmaceutical industry grapples with intense financial pressures due to an increasingly cost-constrained and highly regulated health care environment, finite patent expiries on blockbuster drugs, generic competition, decreases in effective market exclusivity from new innovations, and a proliferation of smaller markets due to the escalating molecular segmentation patients populations (i.e., personalized medicine). Specifically, due to dramatic cost reductions in DNA sequencing following the development of “next-generation” sequence platforms in 2008, molecular diagnostics are increasingly being considered to be cost effective enough to be used as a standard medical test, both prospectively for risk assessment and confirmation of diseases---and increasingly, therapeutics. Although the progress in genomics is heralded as a solution to overcome certain rare diseases, some of the ethics and privacy questions to genomic research, such as how whole-person genomic information is collected and stored, and what constitutes informed consent are being vigorously debated. In the midst of these developments, pharmaceutical companies are obliged to reevaluate their drug development strategies and select among alternative future business models in order to stay relevant. Using a dynamic capabilities lens, this paper studied the impact of genomics generally and gene therapy specifically on the rare disease sector of the biopharmaceutical industry. This study found that increasing rates of cumulative returns depends on accumulating knowledgebased employees and expanding product portfolios of disruptive genomics-based technologies for treating rare diseases. Further, thisstudy highlights the importance of building the capability and capacity to absorb expertise and accumulate knowledge for new product innovations and sustainable competitive advantage

Technology Management Maturity Assessment Model in Healthcare

Significant gaps in the practical transformation of clinical knowledge into practices, increasing healthcare costs, costly medical errors, healthcare institutions\u27 obligations towards improving safety, clinical outcomes, and efficacy of care from one side; and the rise of disruptive innovations, the adoption of electronic health records and novel diagnostic tools, and the plethora of data from the other side has made the need for a new approach in managing the U.S healthcare systems an imperative. Continuous learning has been utilized to mitigate some of these issues have been in healthcare organizations. Continuous learning is especially important in the research centers that act as innovation hubs within University Hospitals. These centers align with learning and improving current systems and practices in a specific area of healthcare with goals of better serving the population in need of those specific services or treatments. Maturity Models are organizational management tools that have been used as a way of responding to the constant pressure of trying to achieve and maintain competitive advantage through concurrent innovation, quality improvement, and cost reduction. In the context of continuous learning in healthcare organizations, a mature system can be defined as a system that generates timely actions to the information that it derives from internal and external data to create meaningful measurement regarding system learning and increased efficacy and effectiveness in health outcomes. However, there is a lack of a model that provides managers and decision-makers with a systematic, multi-criteria, validated, quantifiable, and repeatable maturity model to assess and enhance health organizations\u27 performance in continuous learning and technology management. This research proposes a multi-criteria model to assess technology management maturity and continuous learning in research centers within university hospitals by using Hierarchical Decision Model (HDM). The model can help these research centers with pinpointing their strengths and opportunities in terms of continuous learning from the data they have access to while giving them organizational self-awareness and guide them in setting their strategies and resource allocation. The model will serve as a much-needed technology management tool for healthcare organizations to assess their technology management maturity and continuous learning efforts and assist them in creating more effective roadmaps

Technology Management Maturity Assessment Model in Healthcare Research Centers

In the context of continuous learning in healthcare organizations, a mature system can be defined as a system that generates timely actions to the information that it derives from internal and external data to create meaningful measurement regarding system learning and increased efficacy and effectiveness in health outcomes. However, there is a lack of a model that provides managers and decision-makers with a systematic, multi-criteria, validated, quantifiable, and repeatable maturity model to assess and enhance health organizations\u27 performance in continuous learning and technology management. This research proposes a multi-criteria model to assess technology management maturity and continuous learning in research centers within university hospitals by using Hierarchical Decision Model (HDM), validated and quantified by panels of healthcare subject matter experts. The model can help research centers with pinpointing their strengths and opportunities in terms of continuous learning from the data they have access to while giving them organizational self-awareness and guide them in setting their strategies and resource allocation. The model will serve as a much-needed technology management tool for healthcare organizations to assess their technology management maturity and continuous learning efforts and assist them in creating more effective roadmaps

Genomics, Rare Diseases, and Disruptive Innovation in the Biopharmaceutical Industry

The multinational biopharmaceutical industry has to deal with significant financial pressures due to being a very cost-constrained and highly regulated industry. To add to that, finite patent expirations on financially successful drugs, vying nature of the biotech industry due to new innovations. There has been an increase of smaller markets due to the proliferation of molecular segmentation patient populations in fields such as personalized medicine. Particularly, due to the significant cost reducing impacts of the development of next-generation sequence platforms on DNA sequencing in the last decade, molecular diagnostics are being considered as cost effective candidates to be used as a standard medical test, in terms of risk assessment, confirmation of diseases, and therapeutics. Biopharmaceutical companies need to reassess their drug development strategies and choose among alternative prospective business models in order to remain relevant amid the new innovations and developments. Using a dynamic capabilities lens, this paper tends to study the impact of genomics generally and gene therapy specifically on the rare disease sector of the biopharmaceutical industry by analyzing the public data from 24 genomics based rare disease focused biopharmaceutical companies. This study shows that growing rates of cumulative returns is dependent upon the accumulation of knowledge-based employees and expanding product portfolios of disruptive genomics-based technologies for treating rare diseases. Further, this study stresses the significance of structuring the capability and capacity to absorb expertise and accrue knowledge for new product innovations and viable competitive advantage

Energy Technology Adoption: Case of Solar Photovoltaic in the Pacific Northwest USA

Current political, economic, and environmental issues have made energy source selection a delicate decision. These pressures concurrent with the decrease in sustainable energy costs have increased the interest in cleaner alternative energies such as solar and wind in order to mitigate the environmental consequences. Among these energies, solar photovoltaic (PV) energy is one of the most promising sources of power with the potential of providing one fifth of the annual energy in US alone. The purpose of this study is to analyze the associations and correlations of income, education, and solar adoption through surveys and Geographic Information Systems (GIS) respectively. Results from GIS analysis and linear regression show correlations between education, income levels, and the number of solar PV adopters in Oregon census tracts. By identifying adoption hotspots, this study recommends four areas in Oregon State which are ideal for energy companies to promote, educate, and incentivize Solarize programs in order to bolster the adoption and diffusion of solar PVs. The selected areas have high income and education levels but the number of solar adoptions are not significant which makes them good candidates for more analysis and potentially incentives and education programs

R&D Project Evaluation: Technology Transfer Focus

This research develops a decision model that obtains a technology transfer score. These scores can be used to evaluate the technology transfer potential of different research proposals bolstering organizations’ development of a research portfolio. In a highly competitive global market, an organization’s growth and success depends on having better R&D performance followed by the ability turn the results into application. This model can be used by organizations with goals of selecting and the proposals with outcomes that have higher potential of moving into successful application. This increase in success can be achieved by helping an organization make informed and deliberate decisions about their research portfolio

Impact of Genomics on Biopharmaceutical Industry: Rare Diseases as Disruptive Innovation

Purpose Using a dynamic capabilities lens, this paper aims to study the impact of genomics generally and gene therapy specifically on the rare disease sector of the biopharmaceutical industry. Design/methodology/approach In this study, 24 genomics-based, rare disease-focused biopharma companies were studied and several variables were tested with respect to enterprise value growth. The companies were analyzed as a group of rare disease firms, as well as by size. Findings The authors found that number of employees, revenues, number of pipeline and marketed products and retained earnings are strongly correlated (in that order) with enterprise value in rare disease focused biopharma companies. These correlations seem to be weaker as a company’s market capitalization size decreases, indicating that there tends to be increasing returns to scale. Research limitations/implications This study found that increasing rates of cumulative returns to enterprise value growth depends on accumulating knowledge-based employees and expanding product portfolios of disruptive genomics-based technologies for treating rare diseases. Aggregating skilled and innovative employees (especially in bigger companies) can be seen as a cumulative bolstering factor in leveraging dynamic capabilities which can be recognized, understood and transformed into commercial success (i.e. increasing returns in enterprise value). In other words, technology managers’ job is to manage not only the financial aspects of the technology but also human resources, asset configuration and strategic alliances efficiently toward faster and better innovation. Strong dynamic capabilities can be formed with the accumulation of experience, articulation and codification of knowledge and an adaptive ability to change the way they solve problems as their environment transforms. Originality/value This is the first study to demonstrate and measure a relationship between dynamic capabilities and enterprise value in genomics-based rare disease firms. Further, this study highlights the importance of building the capability and capacity to absorb expertise and accumulate knowledge for new product innovations and sustainable competitive advantage in industries characterized by disruptive innovation

Half a century of promises The failure to realise 'community care' for older people

1994 Graham Lecture, London (Great Britain), 10 Nov 1994Available from British Library Document Supply Centre- DSC:q95/03815 / BLDSC - British Library Document Supply CentreSIGLEGBUnited Kingdo